Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing at the ICGEB
28 June 2023 - 11:00PM
June 28, 2023 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC:
SRBCF) ("
Sirona") is excited to announce the
development of a promising new set of potential antiviral compounds
which will undergo testing at the renowned International Centre for
Genetic Engineering and Biotechnology (
ICGEB). The
compounds, generated by Sirona's subsidiary TFChem, are aimed at
expanding Sirona's existing library of antiviral drug candidates.
The ICGEB, located in Trieste, Italy, will
employ specialized assays developed at their Laboratory of
Molecular Virology to screen a library of 18 newly produced
candidates, for their potential to inhibit SARS-CoV2. Spearheading
the research program is Dr. Alessandro Marcello, a globally
recognized authority in Human Virology.
Building upon the previous screening results of
the initial 20 compounds, these newly selected candidates hold
significant promise. Testing is slated to commence within the next
month.
Sirona Biochem remains committed to advancing
the program on antiviral research and remains optimistic about the
potential impact these new compound candidates may have in
combatting viral diseases.
About the International Centre for Genetic
Engineering and Biotechnology
Established in 1983 as a special project of
UNIDO, the International Centre for Genetic Engineering and
Biotechnology – ICGEB is an independent intergovernmental
organization with HQ in Trieste (Italy) and with additional
laboratories in New Delhi (India) and Cape Town (South Africa). It
counts almost 70 Member States. The ICGEB is a not-for-profit IGO –
any revenues generated are re-invested in research and in the
funding programs for capacity building in its Member States. The
Vision of the ICGEB is to be the world’s leading intergovernmental
Organization for research, training, and technology transfer in the
field of Life Sciences and Biotechnology. Its Mission is to combine
scientific research with capacity enhancement, thereby promoting
sustainable global development (https://www.icgeb.org/).
The Molecular Virology Group in Trieste studies
the detection and molecular mechanisms of different arboviruses and
has been mainly involved in the response to the COVID-19 pandemic
providing support to the ICGEB Member countries. Activities
included in the formulation for protocols for SARS-CoV-2 molecular
and serological diagnostics, online tutorials and reagents to be
able to develop low-cost in-house assays. COVID-19 viruses
circulating in several countries have been sequenced for the first
time and made available to the scientific community. A pipeline for
testing antivirals against SARS-CoV-2 has been set-up allowing the
identification of novel drug candidates.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug
discovery company with proprietary platform technology. Sirona
specializes in stabilizing carbohydrate molecules with the goal of
improving efficacy and safety. New compounds are patented for
maximum revenue potential.
Sirona’s compounds are licensed to leading
companies around the world in return for licensing fees, milestone
fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is
located an hour north of Paris, France and is the recipient of
multiple French national scientific awards and European Union and
French government grants. For more information, please visit
www.sironabiochem.com.
For more information regarding this press
release, please contact:Investor Enquiries:Email:
Info@sironabiochem.com
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
---------------------------------------------
Sirona Biochem cautions you that statements
included in this press release that are not a description of
historical facts may be forward-looking statements. Forward-looking
statements are only predictions based upon current expectations and
involve known and unknown risks and uncertainties. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of release of the
relevant information, unless explicitly stated otherwise. Actual
results, performance or achievement could differ materially from
those expressed in, or implied by, Sirona Biochem’s forward-looking
statements due to the risks and uncertainties inherent in Sirona
Biochem’s business including, without limitation, statements about:
the progress and timing of its clinical trials; difficulties or
delays in development, testing, obtaining regulatory approval,
producing and marketing its products; unexpected adverse side
effects or inadequate therapeutic efficacy of its products that
could delay or prevent product development or commercialization;
the scope and validity of patent protection for its products;
competition from other pharmaceutical or biotechnology companies;
and its ability to obtain additional financing to support its
operations. Sirona Biochem does not assume any obligation to update
any forward-looking statements except as required by law.
Sirona Biochem (TSXV:SBM)
Historical Stock Chart
From Dec 2024 to Jan 2025
Sirona Biochem (TSXV:SBM)
Historical Stock Chart
From Jan 2024 to Jan 2025